Trial
NCT02530125
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Northwestern University
Collaborators
Gateway for Cancer Research; National Cancer Institute (NCI)
Condition
Stage III Diffuse Large B-Cell Lymphoma
Intervention
Laboratory Biomarker Analysis
Why stopped
sponsor decided to discontinue development of the study drug.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-03-19